

2011

Regulation of the PMP22 gene through an intronic enhancer

Erin A. Jones

University of Wisconsin - Madison

Camila Lopez-Anido

University of Wisconsin - Madison

Rajini Srinivasan

University of Wisconsin - Madison

Courtney Krueger

University of Wisconsin - Madison

Li-Wei Chang

Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs

 Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Jones, Erin A.; Lopez-Anido, Camila; Srinivasan, Rajini; Krueger, Courtney; Chang, Li-Wei; Nagarajan, Rakesh; and Svaren, John, "Regulation of the PMP22 gene through an intronic enhancer." *The Journal of Neuroscience*.31,11. 4242-4250. (2011).
http://digitalcommons.wustl.edu/open_access_pubs/221

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Authors

Erin A. Jones, Camila Lopez-Anido, Rajini Srinivasan, Courtney Krueger, Li-Wei Chang, Rakesh Nagarajan, and John Svaren

Regulation of the PMP22 Gene through an Intronic Enhancer

Erin A. Jones,¹ Camila Lopez-Anido,³ Rajini Srinivasan,³ Courtney Krueger,³ Li-Wei Chang,⁴ Rakesh Nagarajan,⁴ and John Svaren^{2,3}

¹Program in Cellular and Molecular Biology, ²Department of Comparative Biosciences, and ³Waisman Center, University of Wisconsin, Madison, Wisconsin 53705, and ⁴Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri 63110

Successful myelination of the peripheral nervous system depends upon induction of major protein components of myelin, such as peripheral myelin protein 22 (PMP22). Myelin stability is also sensitive to levels of PMP22, as a 1.4 Mb duplication on human chromosome 17, resulting in three copies of *PMP22*, is the most common cause of the peripheral neuropathy Charcot-Marie-Tooth disease. The transcription factor Egr2/Krox20 is required for induction of high level expression of *Pmp22* in Schwann cells but its activation elements have not yet been determined. Using chromatin immunoprecipitation analysis of the rat *Pmp22* locus, we found a major peak of Egr2 binding within the large intron of the *Pmp22* gene. Analysis of a 250 bp region within the largest intron showed that it is strongly activated by Egr2 expression in reporter assays. Moreover, this region contains conserved binding sites not only for Egr2 but also for Sox10, which is also required for Schwann cell development. Our analysis shows that Sox10 is required for optimal activity of the intronic site as well as *PMP22* expression. Finally, mouse transgenic analysis revealed tissue-specific expression of this intronic sequence in peripheral nerve. Overall, these data show that Egr2 and Sox10 activity are directly involved in mediating the developmental induction of *Pmp22* expression.

Introduction

In the peripheral nervous system, the lipid-rich myelin sheath formed by Schwann cells plays a vital role in axonal function and stability. The myelin sheath is composed of many structural proteins required for the compact structure of myelin and the genes encoding such proteins are highly regulated during development. Genetic defects in the function or level of myelin genes can be detrimental and lead to peripheral neuropathy. Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, affecting ~1 in 2500 people. The most common cause of CMT is a 1.4 Mb duplication of human chromosome 17, containing the *peripheral myelin protein 22* (*PMP22*) gene (classified as CMT type 1A), and a deletion of the same region leads to another type of peripheral neuropathy: hereditary neuropathy with liability to pressure palsies (Lupski et al., 1991; Chance et al., 1993; Suter and Scherer, 2003). *Pmp22* is a tetraspan protein required for stable myelination (Adlkofer et al., 1995) and a number of rodent models for CMT1A have shown that transgenic overexpression of *Pmp22* causes peripheral neuropathy (Huxley et al., 1996; Magyar et al., 1996; Sereda et al., 1996; Huxley et al., 1998;

Robertson et al., 2002). Importantly, lowering expression of *Pmp22* improves myelination in rodent models of CMT1A (Perea et al., 2001; Sereda et al., 2003; Passage et al., 2004).

Pmp22 is highly upregulated along with other myelin genes in Schwann cells during myelination as well as during remyelination following nerve crush injury (Snipes et al., 1992; Notterpek et al., 1999). Two transgenic studies identified overlapping upstream segments that lead to Schwann cell-specific expression (Maier et al., 2003; Orfali et al., 2005). This upstream region was shown to recapitulate the later expression of endogenous *Pmp22* and has been named the late myelination Schwann cell-specific element (LMSE) (Maier et al., 2003). The region(s) responsible for early developmental expression have yet to be identified.

Early growth response 2 (Egr2/Krox20, hereafter referred to as Egr2) is a key regulator of myelin genes during early development (Topilko et al., 1994; Le et al., 2005b; Decker et al., 2006) and is also required for induction of *Pmp22* (Nagarajan et al., 2001; Le et al., 2005a). Sox10 is required at several stages of Schwann cell development (Kuhlbrodt et al., 1998; Britsch et al., 2001; Schreiner et al., 2007; Finzsch et al., 2010) but has not been shown to directly regulate *Pmp22*. Interestingly, Sox10 binds near Egr2 at several loci in myelin genes (Jang et al., 2010) and has been shown to function synergistically with Egr2 at the *myelin protein zero* (*Mpz*) locus (Bondurand et al., 2001; Denarier et al., 2005; LeBlanc et al., 2006; Jang and Svaren, 2009). Because of their fundamental role in Schwann cell biology (Svaren and Meijer, 2008), we hypothesize that identifying the Egr2/Sox10 regulated sites will reveal critical regulatory elements within *PMP22*. Here we use chromatin immunoprecipitation (ChIP) of Egr2 and Sox10 to identify a novel enhancer that drives Schwann cell-specific expression of *Pmp22*.

Received Nov. 8, 2010; revised Jan. 17, 2011; accepted Jan. 21, 2011.

This work was supported by grants from the Charcot-Marie-Tooth Association, National Institutes of Health (R01 HD41590), and its American Recovery and Reinvestment Act supplement (HD041590-09S1) to J.S., and a core grant to the Waisman Center from the National Institute of Child Health and Human Development (P30 HD03352). E.A.J. was supported by the Wayne and Jean Roper Distinguished Graduate Fellowship. We thank Richard Quarles for providing the S16 cell line and Alyssa Johnson, Jennifer Abraham, Gennifer Mager, Holly Hung, and Sung-Wook Jang for technical assistance. We also thank Albee Messing for assistance with transgenic analysis.

The authors declare no competing financial interests.

Correspondence should be addressed to John Svaren, 1500 Highland Avenue, Waisman Center, University of Wisconsin, Madison, WI 53705. E-mail: jpsvaren@wisc.edu.

DOI:10.1523/JNEUROSCI.5893-10.2011

Copyright © 2011 the authors 0270-6474/11/314242-09\$15.00/0

Table 1. Primer sets used in quantitative PCR

Name	Forward primer	Reverse primer
–7 kb	TCTGAGCTTCTCTCCACAG	TCCCAGGATGAAGTGCATCTT
–2 kb	AGGCCCGCCTCTGCACAG	TTTGCCTGCTGCAGAAAG
+5 kb	TTCCTCAGGTGAGCAAAGTCTTG	AAGGCCCCACATGGATA
+6.5 kb	CCTGGTGTGTTGATTCATTTTT	CAGGCCAGGTGAAATCAAGAC
+8.5 kb	CCCAGGCCACTTCTCAGA	ACCAATGCCCTACAGTTCTAATGTT
+11 kb	CACTGGCCTCTGGGCAAGT	GAAACAATGTGGCCTTTGCTC
+16 kb	TATTTTTGCTTCTGGAGATGTTCTT	GGAGAGGCTTCCAACATATGATTG
+24 kb	TCCCTCTATCGCAAAC	TGAGTGAAGTGAAGCAGTACCTATTGG
Luciferase	GGCTACTGATCTGCGGCTT	TCCTCTCGAAGCGGTACAT
End Pmp22	GAGGAAGGGGTACACCATTG	GCAACTAGCACCCGGAT
End Mpz	CCCTGGCCATTGTGGTTTAC	CCATTCAGTACCAGAAAGGAG
Hmgcr	GGATGGTACCGGTGCTCT	AGAAACGAACGTAGTCTC

Materials and Methods

Chromatin immunoprecipitation. ChIP assays on pooled male and female rat sciatic nerve at postnatal day (P)15 and the S16 cell line were performed as previously described (Jang et al., 2006; Jang and Svaren, 2009), except that the S16 cell line was cross-linked in PBS containing 1% formaldehyde. In addition, the herring sperm DNA in the blocking procedure was omitted in the *in vivo* ChIP assays. The antibodies used in this study include Egr2 (Covance PRB-236P), Sox10 (Santa Cruz Biotechnology sc-17342X), and control IgG (normal rabbit IgG, Millipore 12-370; normal goat IgG, Santa Cruz Biotechnology sc-2028). Following ChIP, quantitative PCR was performed in duplicate to calculate the fold recovery of a given segment relative to the nonspecific control, using the comparative Ct method (Livak and Schmittgen, 2001). All the primers used in this study are listed in Table 1. All experiments on rats/mice were performed in strict accordance with experimental protocols approved by the Institutional Animal Care and Use Committee, University of Wisconsin, School of Veterinary Medicine.

ChIP analysis using tiled microarrays. To combine ChIP with microarray analysis, amplicons were first generated from ChIP products by whole genome amplification (Sigma). Labeling of the samples with Cy5 (Egr2; Covance) or Cy3 (IgG), followed by microarray hybridization, was performed as described previously (Jang and Svaren, 2009; Jang et al., 2010) by Nimblegen, using a custom microarray designed with isothermic probes staggered by 17 bp over the *Pmp22* locus. Coordinates of tiled regions are derived from the Rn4 genome build. Gaps in the tiling represent repetitive DNA regions for which unique probes could not be designed. The enrichment ratio of Cy5 to Cy3 was plotted on a log₂ scale, further processed by baselining all peaks to 1% of the highest peak in the window, and displayed a moving average using a window size of five probes. Peak finding was performed using the NimbleScan (Nimblegen) software, with a false discovery rate of 0.05.

Formaldehyde-assisted isolation of regulatory elements. The formaldehyde-assisted isolation of regulatory elements (FAIRE) assay on the S16 rat Schwann cell line was performed by first rinsing confluent cells with PBS and then cross-linking in PBS containing 1% formaldehyde for 5 min at room temperature (22°C). Glycine was added to 125 mM and incubated for 5 min at room temperature. After washing twice with cold PBS, the cells were harvested, pelleted, and frozen at –80°C. The cell pellet was thawed and sonicated on ice using the Bioruptor (Diagenode) set on high (30 s on, 30 s off; for 20 min) in lysis buffer (150 mM NaCl, 10% glycerol, 50 mM Tris pH 8.0, 2% Triton, 1% SDS, 1 mM EDTA) containing protease inhibitor mixture (5 μl of mixture per milliliter of buffer) (Sigma). The lysate was cleared by centrifugation and unbound DNA was extracted with phenol:chloroform and ethanol precipitated, as previously described (Giresi and Lieb, 2009). The protocol only differed in that NaCl was used in the ethanol precipitation. Twenty percent of the cross-linked chromatin was used as an input control by reversing the cross-links at 65°C overnight before phenol:chloroform extraction. The samples were analyzed using quantitative PCR with the same primer sets used in ChIP (Table 1), performed in duplicate to calculate the relative expression, of a given

segment relative to the input control, using the comparative Ct method (Livak and Schmittgen, 2001).

Transfection assays. The B16 (mouse melanoma) cell line was grown and transfected as described previously (Jones et al., 2007; LeBlanc et al., 2007). The reporter constructs contain the following coordinates from human chromosome 17 (hg18Mar. 2006 build in UCSC Genome Browser), cloned upstream of the pGL4 luciferase reporter containing the minimal E1B TATA promoter except the PMP22 –2 kb construct that contains the native *PMP22* P2 promoter; PMP22 –7 kb: 15,113,094–15,114,102; PMP22 –2 kb: 15,106,498–15,106,933; PMP22 +5 kb: 15,098,299–15,098,685; PMP22 +8.5 kb: 15,094,466–15,094,975; PMP22 +11 kb: 15,091,959–15,092,201; PMP22 +16 kb: 15,086,052–15,086,906; PMP22 +24 kb: 15,075,138–15,075,801. The mutations of the PMP22 +11 kb reporter were made using site-directed mutagenesis. The individual Sox10 sites were changed to G at positions 4 and 5 on the CA-rich strand, which has been previously reported to abrogate Sox10 binding to DNA (Bondurand et al., 2001). The Egr2 sites were mutated to A at position 6 of the G-rich strand, which has previously been shown to abolish binding (Choo et al., 1997).

siRNA treatment and Western blot analysis. Either siRNA directed toward Sox10 (4390771; Ambion) or a negative siRNA control (Negative control #2, AM4613; Ambion) were transiently transfected into S16 cells with the Amaxa system (Lonza) using the rat neuron nucleofection solution. The transfected cells were incubated for 48 h before harvesting RNA using Tri Reagent (Ambion), and quantitative PCR was performed in duplicate to calculate the relative expression, using the comparative Ct method (Livak and Schmittgen, 2001).

Lysates from siRNA-treated S16 cells were analyzed by immunoblotting for Sox10 and Pmp22 using a 1:1000 dilution of Sox10 (Santa Cruz Biotechnology) and a 1:1000 dilution of Pmp22 (Abcam). The membranes were probed with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Jackson Laboratories) at a dilution of 1:10,000. Luminescence was detected with ECL Plus (Invitrogen) using the Alpha Innotech Fluorochem HDII imaging system.

Bioinformatic analysis. Regions conserved between humans, rats, and mice in a 40 kb window surrounding the *Pmp22* locus were searched for Egr2/Sox10 binding sites using a conserved composite element module previously described (Jones et al., 2007).

Transgenic mice. The transgene used in this study contains the following coordinates from the human genome (Mar. 2006 build in UCSC Genome Browser), cloned upstream of the pGL4 luciferase reporter containing the mouse Hsp68 promoter: chr17: 15,090,965–15,092,611. The transgene was linearized by restriction digestion (KpnI and SalI) and microinjected into the pronucleus of FVB/N one-cell embryos by the University of Wisconsin Waisman Center Rodent Models Core. Relative copy number of each founder was determined by using quantitative PCR to normalize the transgene to an endogenous gene, *Hmgcr*. At P4, P12, and P30, various tissues were collected from both male and female mice for luciferase expression analysis by quantitative reverse transcription PCR.

Immunohistochemistry. Frozen sections of mouse sciatic nerve (6 μm) were fixed in 4% paraformaldehyde in PBS for 15 min at room temperature. After the sections were rinsed with PBS, they were incubated with permeabilizing solution (0.06% Triton X-100 in PBS) for 20 min. They were rinsed three times with PBS and incubated in blocking solution (5% goat serum, 1% BSA in PBS) for 1 h. Sections were incubated with anti-firefly luciferase (Luc-17) mouse monoclonal antibody (1:100; Abcam) for 1 h. They were rinsed three times with PBS and incubated with Alexa-488 secondary antibodies for 1 h. After the sections were rinsed once with PBS, they were incubated with Hoescht 33258 (1:1000; Fisher Scientific) in PBS for 1 min and then rinsed five times with PBS. The sections were mounted on slides using Fluoromount-G mounting medium (Southern Biotech). Immunofluorescent images were visualized via a Nikon CI confocal microscope.

Results

Identification of Egr2 binding sites in *Pmp22*

PMP22 is expressed from two different promoters, P1 and P2, transcribing exon 1A and exon 1B, respectively, which result in

two mRNAs that differ only in their 5' noncoding region (Bosse et al., 1994; Suter et al., 1994). Both the P1 and P2 promoters are upregulated during myelination, but expression from P1 is Schwann cell-specific, whereas P2 is expressed in other tissues, such as brain, heart, lung, and gut. As myelination progresses, the transcript originating from P1 becomes the predominant form in rodent peripheral nerve, whereas the ratio of P1 to P2 in human peripheral nerve is approximately equal (Suter et al., 1994). Transfection studies of *Pmp22* expression have shown that the P1 promoter can drive expression of a reporter in Schwann cells (Suter et al., 1994; Sabéran-Djoneidi et al., 2000; Hai et al., 2001). However, additional regulatory elements are involved since the P1 promoter is unable to independently drive consistent expression in peripheral nerve of transgenic mice (Maier et al., 2003).

Since *Egr2* activates *Pmp22* expression (Nagarajan et al., 2001; Le et al., 2005a), we sought to identify *Egr2* binding sites as a means to discover critical *Pmp22* enhancer elements. We therefore adapted *Egr2* ChIP assays in the S16 rat Schwann cell line for analysis with a tiled microarray (ChIP–chip) containing 200 kb surrounding the rat *Pmp22* gene (Fig. 1A). The S16 cell line expresses high levels of myelin genes, including *Pmp22*, comparable to those in myelinating Schwann cells (Hai et al., 2002). *Egr2* ChIP DNA was cohybridized to the custom array along with control IgG ChIP DNA, and the fluorescence ratio was plotted relative to the position within the *Pmp22* locus. The results show a major peak at +11 kb (relative to the translation start site) within the largest intron of the *Pmp22* gene, along with some more minor peaks distributed throughout the gene.

Several sites with various levels of *Egr2* binding were chosen for further analysis (Fig. 1A, arrows). The site at –7 kb is within a larger region previously shown to drive Schwann cell-specific expression in mice (Maier et al., 2003; Orfali et al., 2005). The –2 kb region is just upstream of the P2 promoter, expressing exon 1b. Several intronic sites in uncharacterized regions of *Pmp22* were also chosen for further analysis, including the major peak at +11 kb. *Egr2* binding at these sites was validated by quantitative PCR analysis of independent ChIP samples from the S16 cell line, revealing high levels of *Egr2* at +11 kb relative to a control immunoprecipitation (Fig. 1B). Moreover, we also performed *in vivo* ChIP assays using P15 rat sciatic nerve, which is an optimal time point for detection of *Egr2* binding by ChIP (Jang et al., 2006; Mager et al., 2008; Jang and Svaren, 2009). The *in vivo* ChIP assay demonstrated a significant level of binding at +11 kb, consistent with the ChIP assays in the S16 cell line (Fig. 1C). Many of the minor peaks in the ChIP–chip analysis do not exhibit significant *Egr2* binding above background in quantitative PCR analysis of ChIP samples from S16 cells or *in vivo*. The +11 kb region appears to be the predominant region for *Egr2* binding during myelination.




Figure 1. ChIP–chip analysis of the *Pmp22* locus. **A**, ChIP–chip analysis of *Egr2* binding was performed in S16 rat Schwann cells with a custom tiled array containing the *Pmp22* locus. The enrichment ratio of Cy5-labeled *Egr2* ChIP DNA to Cy3-labeled IgG ChIP DNA was plotted on a log₂ scale and further processed by baselining to 1% of the highest peak and displayed a five-point moving average. Peak analysis was performed (NimbleScan) with a false discovery rate of 0.05. A significant peak at +11 kb was observed in two independent *Egr2* ChIP–chip experiments and the peak at +6.5 was only detected in one of the two experiments. Below, Noncoding exons (white boxes), coding exons (gray boxes), alternative transcription start sites (P1 and P2), and regions chosen for further analysis (downward arrows) with their distance relative to the translation start site are indicated. **B**, S16 ChIP assays for *Egr2* binding were analyzed by quantitative PCR with indicated primer sets. The graph indicates fold enrichment at each site relative to an IgG control ChIP assay. Error bars represent the SD of two technical replicates. The fold enrichment of the signal at the +11 kb site was at least ninefold in three independent experiments. **C**, *In vivo* ChIP assays for *Egr2* binding were performed using pooled P15 rat sciatic nerve and analyzed by quantitative PCR using the same primer sets as in **B**. Error bars represent the SD of two technical replicates. The fold enrichment of the signal at the +11 kb site was at least eightfold in three independent experiments.

Activation of PMP22-derived segments in reporter assays

To determine whether *Egr2*-bound regions have enhancer activity, many of the regions chosen for further analysis in the ChIP assay were tested for their response to *Egr2* expression in a luciferase reporter assay. Segments were cloned upstream of a minimal TATA promoter driving luciferase except –2 kb, which contains the P2 promoter (Fig. 2A, arrows). As many of these segments contained conserved sequences, the homologous human sequences were used to create the reporter vectors.

The reporters were tested in the B16/F10 melanoma cell line, which expresses Sox10 (Kamaraju et al., 2002) but not *Egr2* (Slutsky et al., 2003), for activation by cotransfection of an *Egr2* expression construct. The +11 kb reporter from the largest intron was highly activated in response to *Egr2*, whereas the other six reporters were not strongly activated. The +11 kb region also showed the strongest *Egr2* binding in the ChIP assays (Fig. 1), indicating that *Egr2* binding is correlated with enhancer activity in this assay.

Identification of functional Sox10 and *Egr2* sites in the +11 kb enhancer

Analysis of the human +11 kb element revealed four putative *Egr2* sites and one putative dimeric Sox10 site, which are variably conserved in the rat, mouse, and human genomes (Fig. 2B). The +11 kb reporter construct used above was mutated to test the importance of these sites in *Egr2* activation. The *Egr2* sites were




Figure 2. Reporter analysis of selected human *PMP22* segments. **A**, The indicated segments of the human *PMP22* gene were placed upstream of a luciferase reporter gene containing a minimal TATA element, except the -2 kb reporter, which contains the *PMP22* P2 promoter. The *PMP22* reporters were cotransfected in the B16/F10 cell line with expression plasmids for Egr2 (25 and 50 ng). Fold induction is calculated relative to the activity of each reporter alone and reported on a \log_{10} scale. Error bars represent SD ($n = 6$). **B**, The $+11$ kb region of human *PMP22* is diagrammed with four putative Egr2 sites (numbered boxes) and one putative dimeric Sox10 site (ovals). The sequence alignments show conservation of the binding sites in humans (h), mice (m), and rats (r). The monomeric Sox10 binding sites are underlined and the nucleotides mutated by site-directed mutagenesis are indicated (*).

mutated to A at position 6 of the G-rich strand, which has previously been shown to abolish binding (Choo et al., 1997). When all four sites were mutated, the Egr2 activation was abolished (Fig. 3A). To determine which of the four Egr2 sites are functional, the Egr2 sites were each mutated individually (Fig. 3B). Transfection analysis of the resulting promoter constructs showed that mutating Egr2 site 2 had the largest effect, whereas reporter activity was relatively unimpaired by mutation of sites 1 or 3. There was an $\sim 50\%$ decrease with mutation of site 4.

Subsequently, reporter constructs were created in which all but one of the putative Egr2 sites were mutated (Fig. 3C). In this series, the construct containing Egr2 site 2 was most highly activated, yielding a 179-fold activation, which is approximately one-fifth of the activity of the wild-type element. Egr2 sites 3 and 4 support a lower level of activation in this assay, suggesting that they can mediate some of the Egr2 activation. In both sets of constructs, the Egr2 site 1 does not appear to contribute to reporter activity (Fig. 3B,C). Therefore, sites 2–4 appear to be largely responsible for the strong activation of the $+11$ kb element in transfection assays. Using a recently defined binding site




Figure 3. Functional analysis of Egr2 and Sox10 sites within the $+11$ kb enhancer. **A**, Mutated sites are indicated by filled symbols, and the various mutant $+11$ kb reporters were cotransfected in B16/F10 cells with expression plasmids for Egr2 (25 ng). Fold induction is calculated relative to the luciferase activity of each reporter alone. Error bars represent SD ($n = 6$). **B**, The four Egr2 sites were mutated by site-directed mutagenesis, indicated by filled symbols. The reporters were cotransfected in B16/F10 cells with expression plasmids for Egr2 (25 ng). Fold induction, means, and SD ($n = 6$) are calculated as in **A**. **C**, Reporter constructs were created in which all but one Egr2 site was mutated, indicated by filled symbols. The reporters were tested for Egr2 induction as in **B** ($n = 6$).

matrix for Egr1 (Berger et al., 2006), which has an identical DNA binding domain to Egr2, sites 2 and 3 are most conserved, especially at the bases that are most critical for binding. Although Egr2 site 4 in the human sequence would be predicted to be a high affinity site, it is less well conserved in rat and mouse.

To determine whether the Sox10 site is functional, the adenines at positions 4 and 5 of the CA rich strand (AACAAAG) were mutated to G in both sides of the dimeric Sox10 site, which has previously been shown to disrupt Sox10 binding (Bondurand et al., 2001). Mutating the Sox10 sites lowered the Egr2-dependent activation, suggesting that Egr2 activation requires Sox10 binding at this site (Fig. 3A). Although the B16/F10 cell line expresses Sox10, cotransfection of 100 ng of Sox10 expression plasmid further activated the $+11$ kb reporter 14-fold ± 2.4 . The Sox10 mutation decreased Sox10 activation of the $+11$ kb reporter to 1.8-fold ± 0.3 , suggesting that this is a functional Sox10 site and the $+11$ kb element is dependent on both Egr2 and Sox10 for activation.

Sox10 regulates Pmp22

Since the dependence of *Pmp22* expression on Sox10 activity has not been tested previously, we examined *Pmp22* levels in S16 Schwann cells treated with siRNA directed against Sox10 (Fig. 4A). At 48 h after transfection, quantitative reverse transcriptase (RT)-PCR analysis revealed a significant decrease in Sox10 mRNA levels, and Western analysis showed a decrease in Sox10 protein (Fig. 4A,B). This reduction was observed for both *Pmp22* transcripts using primer sets specific for exons 1a and 1b. Similar results were obtained using two independent siRNAs directed toward Sox10 (data not shown).

Previous work has shown that Sox10 is required for expression of *Egr2* in myelinating Schwann cells (Ghislain and Charney, 2006; Finsch et al., 2010; Reiprich et al., 2010). Consistent with these findings, *Egr2* levels were reduced by Sox10 depletion in the S16 cell line. Since the effect of Sox10 on *Pmp22* expression could be mediated indirectly through regulation of *Egr2*, ChIP assays were used to detect Sox10 binding within the *Pmp22* locus (Fig. 4C,D). ChIP assays were performed using an antibody directed against Sox10 in both the S16 rat Schwann cell line and *in vivo* using rat sciatic nerve. The Sox10 ChIP was analyzed using the same primer sets used to detect *Egr2* occupancy and revealed that Sox10 coincides with *Egr2* binding at the +11 kb site. However, we also observed Sox10 binding at other sites across *Pmp22*, with the highest amount of Sox10 binding at the -7 kb site that resides within the previously defined LMSE (Maier et al., 2003).

To test the specificity of the Sox10 ChIP assays, the same assay was also performed in S16 cells in which Sox10 levels were depleted by Sox10 siRNA (Fig. 4C). For the sites examined, the percentage recovery was severely reduced, indicating that the ChIP assays detected specific binding of Sox10 to those sites. Accordingly, the Sox10 antibody detects a single band in the Western blot (Fig. 4B).

Egr2 and Sox10 bound regions are in regions of open chromatin

To further test for common characteristics of enhancer elements, FAIRE was used in S16 cells to identify areas of open chromatin (Giresi et al., 2007), which are typically present in regulatory regions (Felsenfeld and Groudine, 2003). This technique relies on the fact that enhancers often reside in nucleosome-depleted regions. Because DNA is most efficiently cross-linked to histones by formaldehyde, phenol extraction of protein-cross-linked DNA results in preferential enrichment of nucleosome-free regions of the genome. The FAIRE analysis shows that there is selective enrichment of DNA surrounding the -7 kb, -2 kb, and +11 kb regions, consistent with areas of open chromatin (Fig. 5). We expected the -2 kb region to have open chromatin because it is directly upstream of the active P2 promoter (Hai et al., 2002), and FAIRE specifically enriches for nucleosome-free regions at promoters of highly transcribed genes (Hogan et al., 2006). Similar regions of open chromatin were found in a previous




Figure 4. Regulation of *Pmp22* by Sox10. **A**, S16 cells were transfected with siRNA targeted to Sox10. Quantitative RT-PCR was used to compare the mRNA levels of *Sox10* and *Pmp22* expression, using promoter-specific primers for the P1 and P2 promoters of the *Pmp22* gene. Levels in the Sox10 siRNA-treated cells (siSox10) were normalized to the negative control (siCon). Error bars represent SD ($n = 3$). **B**, Protein lysates from S16 cells treated with the indicated siRNAs were blotted with antibodies directed toward Sox10 and *Pmp22* relative to actin or β -tubulin as a loading control. The bottom two bands correspond to the previously described 18 and 22 kd bands (Pareek et al., 1997). **C**, Sox10 ChIP assays were performed in S16 rat Schwann cells treated with either control or Sox10 siRNA. Samples were analyzed using quantitative PCR and percentage recovery is calculated relative to input. Error bars represent the SD of two technical replicates. The signal was diminished in the siSox10 sample by an average of 20-fold at the -7 kb site and an average of 21-fold at the +11 kb site in three independent experiments. **D**, *In vivo* Sox10 ChIP was performed using pooled sciatic nerve from P15 mice alongside an IgG control, using the same primer sets as shown in **C**. Error bars represent the SD of two technical replicates. The signal was enriched an average of 12-fold at the -7 kb site and an average of 3.5-fold at the +11 kb site in three independent experiments.

study from our lab using *in vivo* FAIRE from P15 rat sciatic nerve (Jang et al., 2010). The regions of open chromatin at -7 kb and +11 kb are consistent with the hypothesis that these are enhancer elements.

Sequence analysis of Egr2 and Sox10 sites in the *Pmp22* locus

The *Pmp22* locus was also screened for conserved occurrences of a composite matrix containing consensus sequences for both *Egr2* and dimeric Sox10 sites. Using a composite matrix provided a more reliable prediction of enhancer elements in myelin genes than identification of *Egr2* or Sox10 sites alone (Jones et al., 2007). Performing this screen for composite sites conserved in mouse, rat, and human *PMP22* genes identified three regions that contain the Sox/*Egr2* binding module (Table 2). One region is at the +11 kb site, a second is at the -7 kb site, and the third is at +45 kb in relation to the translation start site and far downstream of the 3' end of *Pmp22*. The +45 kb *Egr2* sequence has an A at position 6 of the G-rich strand, which has previously been shown to abolish binding (Choo et al., 1997), making this a poor site. Our data have shown that the intronic enhancer at +11 kb is regulated by *Egr2* and Sox10, again showing that this composite matrix has predictive value. We did observe high levels of Sox10 binding at the -7 kb sites, and there was a small response of this region to Sox10 in transfection studies (data not shown). However, reporter studies of this site failed to show any response to *Egr2*, and the ChIP data showed relatively low binding of *Egr2*. As mentioned, the -7 kb region used here represents only a small portion of a larger region that has been shown previously to drive Schwann cell-specific expression (Maier et al., 2003; Orfali et al., 2005), so it is possible that *Egr2*-responsive elements are located elsewhere within this region.




Figure 5. Analysis of open chromatin in the *Pmp22* locus. A diagram of *Pmp22* indicates regions chosen for FAIRE analysis, in which areas of open chromatin are selectively enriched by phenol extraction of cross-linked chromatin. The percentage recovery was calculated relative to total input. Error bars represent the SD of two technical replicates.

Table 2. Evolutionarily conserved SOX/EGR2 modules found in mouse *Pmp22*

Name of site	SOX position	SOX score	SOX dimer spacing (bp)	EGR position	EGR score	Distance to SOX site
-7 kb	-6533	9.54	4	-6470	5.52	63
+11 kb	11567	8.07	4	11492	4.72	75
				11553	6	14
				11689	6.81	122
+45 kb	49424	8.51	4	49446	5.28	22

Sites within a 100 kb window surrounding the mouse *Pmp22* locus (chr11:62,909,000–63,009,000, mm9) were predicted using a conserved composite matrix described previously (Jones et al., 2007). Such sites conserved in human and rat genomes are shown. The sites are numbered relative to the mouse *Pmp22* P1 promoter.

The +11 kb element drives tissue-specific expression

The LMSE region upstream of *Pmp22*, comprising ~3.5 kb surrounding the -7 kb element, has been shown to drive tissue-specific expression of a *lacZ* reporter in transgenic mice late in development (Maier et al., 2003). We hypothesized that the +11 kb element could also drive tissue-specific expression and may account for earlier developmental expression of *Pmp22*. Transgenic injections were performed with the region surrounding the +11 kb element driving a luciferase reporter with the Hsp68 promoter (Fig. 6A). This promoter has very low levels of expression in peripheral nerve and it has been used extensively to test tissue specificity of regulatory elements in transgenic experiments (Kothary et al., 1988; Rossant et al., 1991; Mandemakers et al., 2000; Forghani et al., 2001; Maier et al., 2003; Visel et al., 2009). Seven of 12 positive founders had luciferase expression in the sciatic nerve but not liver by quantitative RT-PCR analysis (Fig. 6B), suggesting that this region drives tissue-specific expression in Schwann cells. To determine the developmental regulation of the intronic enhancer, lines were developed from two of the founders, lines D and E, and sciatic nerve was sampled at P4 and P12 (Fig. 6C). Both lines had somewhat higher expression at P12 relative to P4, which is similar to two other endogenous myelin genes, *Pmp22* and *Mpz*. P30 mice were also tested for luciferase expression and the expression differed no more than 2.5-fold compared with the expression at P12 (data not shown). Expression at P4 suggests that the +11 kb region, at least in part, accounts for the earlier developmental expression of *Pmp22* in myelinating Schwann cells, since transgenic studies of the upstream LMSE yielded undetectable levels of the reporters at P4 (Maier et al., 2003).

In addition to sciatic nerve and liver, we also sampled heart, lung, kidney, spleen, and brain from lines D and E, and used quantitative RT-PCR to detect luciferase mRNA in these tissues (Fig. 6D). Line E had very high expression in the lung, possibly due to insertion near an active enhancer element in lung. Expression in the sciatic nerve suggests that this element is important to Schwann cell expression of *PMP22* and the residual activity of this +11 kb element in other tissues suggests that it may play a role in the basal level of *Pmp22* mRNA expression observed in other tissues (Suter et al., 1994). Finally, expression of the luciferase protein was observed by immunohistochemistry in sciatic nerve of a P50 mouse from line E (Fig. 6E).

Discussion

The activation of *PMP22* is regulated spatially and temporally to achieve the critical levels of PMP22 required for proper myelin formation. Previous studies have characterized the regions upstream of the *Pmp22* promoter that are critical to its regulation (Suter et al., 1994; Sabéran-Djoneidi et al., 2000; Hai et al., 2001; Maier et al., 2002, 2003; Orfali et al., 2005). However, Maier et al. indicated that other regions of *Pmp22* are likely required, particularly for the early induction of *Pmp22* during myelination. Using ChIP-chip analysis of 200 kb surrounding the *Pmp22* gene, we found a novel +11 kb intronic enhancer driven by both *Egr2* and *Sox10*. Because the region upstream of *Pmp22* has been shown to drive Schwann cell-specific expression late in development, we speculated that the +11 kb enhancer may account for the earlier expression of *Pmp22*, and the transgenic data are consistent with this hypothesis. Since ChIP assays detect higher levels of *Egr2* binding at +11 kb, a possible explanation for the earlier expression of the +11 kb element in transgenic studies is that *Egr2* has a higher affinity for this site. Therefore, *Egr2* must accumulate to higher levels in myelinating Schwann cells to activate the upstream enhancer. However, these elements probably do not act in an isolated manner and it is likely that temporal regulation depends upon looping-mediated interactions between these two enhancers (and perhaps others) and the promoters that set the critical level of *Pmp22* transcription.

Although the -7 kb region was not activated by *Egr2* in reporter assays, it should be noted that the sequences that we used represent only a fraction of the previously reported 3.5 kb LMSE region (Maier et al., 2003), possibly explaining why it was not activated in our *Egr2* activation assays. In the ChIP assays, we observed a high level of *Sox10* binding at -7 kb, whereas *Egr2* binding was higher at +11 kb. In fact, although the -7 kb reporter did not respond to *Egr2* in the transfection assay, it responded slightly to *Sox10* (data not shown). This leads us to speculate that the varying strengths of *Egr2* and *Sox10* binding establish temporally regulated binding at each *PMP22* enhancer and leads to more sensitive regulation of *PMP22* during development.

Previous work has shown that *Egr2* is required for *Pmp22* expression (Nagarajan et al., 2001; Le et al., 2005a), but investigating the role of *Sox10* in regulation of *PMP22* in myelinating Schwann cells has been complicated because of the early embryonic lethality of *Sox10*-null mice (Britsch et al., 2001). Hypomorphic alleles and a conditional knock-out of *Sox10* have been generated that permit further differentiation of Schwann cells (Schreiner et al., 2007; Finzsch et al., 2010), but these fail to activate *Egr2* expression, consistent with previous studies showing that *Sox10* binds to the myelinating Schwann cell enhancer of the *Egr2/Krox20* gene (Ghislain and Charnay, 2006; Reiprich et al., 2010). The RNAi-mediated depletion of *Sox10* in S16 cells

similarly reduced *Egr2* levels, indicating that *Sox10* depletion may indirectly affect *Pmp22* expression through downregulation of *Egr2*. However, direct regulation of *Pmp22* by *Sox10* is supported by the detection of *Sox10* binding in the *Pmp22* locus by ChIP assays, and the observed effects of mutating the *Sox10* site in the +11 kb enhancer.

Both ascorbic acid and progesterone antagonists lower *Pmp22* levels and improve the phenotype in mouse and rat models of CMT1A (Sereda et al., 2003; Passage et al., 2004). Ascorbic acid affects *Pmp22* through inhibition of the cAMP pathway (Kaya et al., 2007) and although it has not been shown directly that *Egr2* is involved, *Egr2* is induced through the cAMP pathway (Zorick et al., 1996). In the case of progesterone antagonists, it also has not been shown directly to involve *Egr2* and *Sox10*, but progesterone induces both *Egr2* and *Sox10* (Guenoun et al., 2001; Magnaghi et al., 2007) and they are presumably downregulated with progesterone antagonist treatment. Although it has not been shown whether *Egr2* or *Sox10* mediate the effects of ascorbic acid or progesterone antagonists, our data support a model of *Pmp22* regulation, at least in part, through *Egr2* and *Sox10*.

Other studies describe the interaction of *Egr2* and *Sox10* in regulatory elements in the *Connexin 32* and *Mbp* genes (BONDURAND et al., 2001; DENARIER et al., 2005), and *Egr2* and *Sox10* bind cooperatively at an intronic regulatory element in *Mpz* and physically interact (LeBlanc et al., 2007). In addition, ChIP–chip analysis of a larger set of myelin genes revealed that *Sox10* colocalizes with *Egr2* more often than would be expected by chance (Jang et al., 2010). Reporter analysis of the intronic element in *Pmp22* revealed that *Egr2* activation of this element is dependent upon *Sox10*. Furthermore, *Pmp22* activation is sensitive to a dominant mutant of *Egr2* (Nagarajan et al., 2001), which disrupts cooperative interactions between *Egr2* and *Sox10* (LeBlanc et al., 2007), suggesting that *Egr2* and *Sox10* are working cooperatively at *Pmp22*. We previously proposed a composite matrix of *Egr2* and *Sox10* binding sites as a means to predict regulatory elements in myelin genes (Jones et al., 2007). Interestingly, application of this matrix to the *Pmp22* gene identified only three such sites in which *Egr2* and *Sox10* binding sites are conserved. One was within the LMSE segment upstream of the gene, and the other coincided with the intron regulatory element that we have characterized. Overall, these data are consistent with a model of *Egr2* and *Sox10* binding in myelin loci, where both *Egr2* and *Sox10* are required for full activation of the loci where they bind.

The upstream and intragenic binding of *Egr2* and *Sox10* is similar to the enhancer pattern found in another highly expressed myelin gene, *Mpz* (Jang and Svaren, 2009). Finding this pattern leads us to hypothesize that this is a common mechanism of transcriptional activation. Perhaps these sites interact, altering the chromatin architecture and leading to transcriptional activa-




Figure 6. The +11 kb enhancer drives developmentally regulated, tissue-specific expression in transgenic mice. **A**, A segment of the human *PMP22* gene containing the +11 kb enhancer was cloned upstream of a luciferase reporter gene and used for transgenic injection. **B**, Relative luciferase expression in sciatic nerve from each transgenic founder was normalized to *18S* ribosomal RNA expression. Expression is shown relative to the highest expressing founder, which was set at 100%. The transgene copy number of each founder is shown below the x-axis. Copy number was determined by normalizing to the endogenous *Hmgb1* gene and is relative to the lowest expressing founder, which was set at 1. **C**, Relative luciferase, endogenous *Pmp22*, and endogenous *Mpz* expression in sciatic nerve and liver were analyzed from two founders at P4 and P12 normalized to *18S* ribosomal RNA expression. Expression levels are shown relative to levels at P4, which are set as 1. **D**, Luciferase expression was determined in two independent transgenic lines at P12 from sciatic (sc.) nerve, brain, lung, heart, spleen, liver, and kidney, and normalized to *18S* ribosomal RNA expression. Expression levels are shown relative to levels in sciatic nerve, which was set as 1. **E**, Sections of transgenic or wild-type (WT) sciatic nerve were stained using an antibody directed against luciferase. The cell nuclei were stained using DAPI. This is representative of two independent experiments.

tion through an unknown mechanism. Enhancer interaction may be promoted by the DNA bending properties of *Sox10* (Werner et al., 1995; Peirano and Wegner, 2000). Further work will be needed to determine whether these elements interact *in vivo*.

Although we have focused on *Pmp22* transcriptional regulation, there is a large body of work on *Pmp22* posttranscriptional regulation. *Pmp22* protein is highly regulated and is turned over quickly by the proteasome (Pareek et al., 1997; Notterpek et al., 1999). A point mutation or extra copies of *Pmp22* lead to an accumulation of the protein that overwhelms the degradation pathway, leading to the CMT1A phenotype (Fortun et al., 2003, 2006). In addition, recent studies of micro-RNAs have found that, whereas *Pmp22* mRNA is expressed in other tissues in addition to peripheral nerve, protein expression is much more selective because of the effects of micro-RNAs (Lau et al., 2008; Verrier et al., 2009). The expression of our transgenic construct in tissues other than sciatic nerve may reflect the lack of known micro RNA binding sites in the *Pmp22* 3' UTR.

Our finding of a new enhancer in *PMP22* has significant therapeutic implications for peripheral neuropathies. It is possible that noncoding mutations in regulatory elements may be associated with human peripheral neuropathies. In addition, regulatory element polymorphisms may be a factor that contributes to the range of severity experienced by CMT1A patients. Finally, identification of key regulatory elements in the *PMP22* gene is

expected to contribute toward development of novel treatment strategies for CMT1A by facilitating identification of compounds that reduce *PMP22* expression.

References

- Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U (1995) Hypomyelination and demyelinating peripheral neuropathy in *Pmp22*-deficient mice. *Nat Genet* 11:274–280.
- Berger MF, Philippakis AA, Qureshi AM, He FS, Estep PW 3rd, Bulyk ML (2006) Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities. *Nat Biotechnol* 24:1429–1435.
- Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, Goossens M (2001) Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. *Hum Mol Genet* 10:2783–2795.
- Bosse F, Zoidl G, Wilms S, Gillen CP, Kuhn HG, Müller HW (1994) Differential expression of two mRNA species indicates a dual function of peripheral myelin protein PMP22 in cell growth and myelination. *J Neurosci Res* 37:529–537.
- Britsch S, Goerich DE, Riethmacher D, Peirano RL, Rossner M, Nave KA, Birchmeier C, Wegner M (2001) The transcription factor Sox10 is a key regulator of peripheral glial development. *Genes Dev* 15:66–78.
- Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B, Swanson PD, Odelberg SJ, Distèche CM, Bird TD (1993) DNA deletion associated with hereditary neuropathy with liability to pressure palsies. *Cell* 72:143–151.
- Choo Y, Castellanos A, García-Hernández B, Sánchez-García I, Klug A (1997) Promoter-specific activation of gene expression directed by bacteriophage-selected zinc fingers. *J Mol Biol* 273:525–532.
- Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, Ghislain J, Vallat JM, Charnay P (2006) Peripheral myelin maintenance is a dynamic process requiring constant *Krox20* expression. *J Neurosci* 26:9771–9779.
- Denarier E, Forghani R, Farhadi HF, Dib S, Dionne N, Friedman HC, Lepage P, Hudson TJ, Drouin R, Peterson A (2005) Functional organization of a Schwann cell enhancer. *J Neurosci* 25:11210–11217.
- Felsenfeld G, Groudine M (2003) Controlling the double helix. *Nature* 421:448–453.
- Finzsch M, Schreiner S, Kichko T, Reeh P, Tamm ER, Bösl MR, Meijer D, Wegner M (2010) Sox10 is required for Schwann cell identity and progression beyond the immature Schwann cell stage. *J Cell Biol* 189:701–712.
- Forghani R, Garofalo L, Foran DR, Farhadi HF, Lepage P, Hudson TJ, Tretjakoff I, Valera P, Peterson A (2001) A distal upstream enhancer from the myelin basic protein gene regulates expression in myelin-forming schwann cells. *J Neurosci* 21:3780–3787.
- Fortun J, Dunn WA Jr, Joy S, Li J, Notterpek L (2003) Emerging role for autophagy in the removal of aggregates in Schwann cells. *J Neurosci* 23:10672–10680.
- Fortun J, Go JC, Li J, Amici SA, Dunn WA Jr, Notterpek L (2006) Alterations in degradative pathways and protein aggregation in a neuropathy model based on *PMP22* overexpression. *Neurobiol Dis* 22:153–164.
- Ghislain J, Charnay P (2006) Control of myelination in Schwann cells: a *Krox20 cis*-regulatory element integrates Oct6, Brn2 and Sox10 activities. *EMBO Rep* 7:52–58.
- Giresi PG, Lieb JD (2009) Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (formaldehyde assisted isolation of regulatory elements). *Methods* 48:233–239.
- Giresi PG, Kim J, McDaniell RM, Iyer VR, Lieb JD (2007) FAIRE (formaldehyde-assisted isolation of regulatory elements) isolates active regulatory elements from human chromatin. *Genome Res* 17:877–885.
- Guennoun R, Benmessahel Y, Delespierre B, Gouézou M, Rajkowski KM, Baulieu EE, Schumacher M (2001) Progesterone stimulates *Krox-20* gene expression in Schwann cells. *Brain Res Mol Brain Res* 90:75–82.
- Hai M, Bidichandani SI, Patel PI (2001) Identification of a positive regulatory element in the myelin-specific promoter of the *PMP22* gene. *J Neurosci Res* 65:508–519.
- Hai M, Muja N, DeVries GH, Quarles RH, Patel PI (2002) Comparative analysis of Schwann cell lines as model systems for myelin gene transcription studies. *J Neurosci Res* 69:497–508.
- Hogan GJ, Lee CK, Lieb JD (2006) Cell cycle-specified fluctuation of nucleosome occupancy at gene promoters. *PLoS Genet* 2:e158.
- Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, Fontés M (1996) Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. *Hum Mol Genet* 5:563–569.
- Huxley C, Passage E, Robertson AM, Youl B, Huston S, Manson A, Sabéran-Djoniedi D, Figarella-Branger D, Pellissier JF, Thomas PK, Fontés M (1998) Correlation between varying levels of *PMP22* expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. *Hum Mol Genet* 7:449–458.
- Jang SW, Svaren J (2009) Induction of myelin protein zero by early growth response 2 through upstream and intragenic elements. *J Biol Chem* 284:20111–20120.
- Jang SW, LeBlanc SE, Roopra A, Wrabetz L, Svaren J (2006) In vivo detection of *Egr2* binding to target genes during peripheral nerve myelination. *J Neurochem* 98:1678–1687.
- Jang SW, Srinivasan R, Jones EA, Sun G, Keles S, Krueger C, Chang LW, Nagarajan R, Svaren J (2010) Locus-wide identification of *Egr2/Krox20* regulatory targets in myelin genes. *J Neurochem* 115:1409–1420.
- Jones EA, Jang SW, Mager GM, Chang LW, Srinivasan R, Gokey NG, Ward RM, Nagarajan R, Svaren J (2007) Interactions of Sox10 and *Egr2* in myelin gene regulation. *Neuron Glia Biology* 3:377–387.
- Kamaraju AK, Bertolotto C, Chebath J, Revel M (2002) Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. *J Biol Chem* 277:15132–15141.
- Kaya F, Belin S, Bourgeois P, Micallef J, Blin O, Fontés M (2007) Ascorbic acid inhibits *PMP22* expression by reducing cAMP levels. *Neuromuscul Disord* 17:248–253.
- Kothary R, Clapoff S, Brown A, Campbell R, Peterson A, Rossant J (1988) A transgene containing lacZ inserted into the dystonia locus is expressed in neural tube. *Nature* 335:435–437.
- Kuhlbrodt K, Herbarth B, Sock E, Hermans-Borgmeyer I, Wegner M (1998) Sox10, a novel transcriptional modulator in glial cells. *J Neurosci* 18:237–250.
- Lau P, Verrier JD, Nielsen JA, Johnson KR, Notterpek L, Hudson LD (2008) Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. *J Neurosci* 28:11720–11730.
- Le N, Nagarajan R, Wang JY, Araki T, Schmidt RE, Milbrandt J (2005a) Analysis of congenital hypomyelinating *Egr2Lo/Lo* nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. *Proc Natl Acad Sci U S A* 102:2596–2601.
- Le N, Nagarajan R, Wang JY, Svaren J, LaPash C, Araki T, Schmidt RE, Milbrandt J (2005b) Nab proteins are essential for peripheral nervous system myelination. *Nat Neurosci* 8:932–940.
- LeBlanc SE, Jang SW, Ward RM, Wrabetz L, Svaren J (2006) Direct Regulation of Myelin Protein Zero Expression by the *Egr2* Transactivator. *J Biol Chem* 281:5453–5460.
- LeBlanc SE, Ward RM, Svaren J (2007) Neuropathy-associated *Egr2* mutants disrupt cooperative activation of myelin protein zero by *Egr2* and Sox10. *Mol Cell Biol* 27:3521–3529.
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2^{(-delta delta C(T))} method. *Methods* 25:402–408.
- Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, Chakravarti A, Patel PI (1991) DNA duplication associated with Charcot-Marie-Tooth disease type 1A. *Cell* 66:219–232.
- Mager GM, Ward RM, Srinivasan R, Jang SW, Wrabetz L, Svaren J (2008) Active gene repression by the *EGR2/NAB* complex during peripheral nerve myelination. *J Biol Chem* 283:18187–18197.
- Magnaghi V, Ballabio M, Roglio I, Melcangi RC (2007) Progesterone derivatives increase expression of *Krox-20* and *Sox-10* in rat Schwann cells. *J Mol Neurosci* 31:149–157.
- Magyar JP, Martini R, Ruelicke T, Aguzzi A, Adlkofer K, Dembic Z, Zielasek J, Toyka KV, Suter U (1996) Impaired differentiation of Schwann cells in transgenic mice with increased *PMP22* gene dosage. *J Neurosci* 16:5351–5360.
- Maier M, Berger P, Suter U (2002) Understanding Schwann cell-neurone interactions: the key to Charcot-Marie-Tooth disease? *J Anat* 200:357–366.
- Maier M, Castagner F, Berger P, Suter U (2003) Distinct elements of the peripheral myelin protein 22 (*PMP22*) promoter regulate expression in Schwann cells and sensory neurons. *Mol Cell Neurosci* 24:803–817.

- Mandemakers W, Zwart R, Jaegle M, Walbeehm E, Visser P, Grosveld F, Meijer D (2000) A distal Schwann cell-specific enhancer mediates axonal regulation of the Oct-6 transcription factor during peripheral nerve development and regeneration. *EMBO J* 19:2992–3003.
- Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J (2001) EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. *Neuron* 30:355–368.
- Notterpek L, Snipes GJ, Shooter EM (1999) Temporal expression pattern of peripheral myelin protein 22 during in vivo and in vitro myelination. *Glia* 25:358–369.
- Orfali W, Nicholson RN, Guiot MC, Peterson AC, Snipes GJ (2005) An 8.5-kb segment of the PMP22 promoter responds to loss of axon signals during Wallerian degeneration, but does not respond to specific axonal signals during nerve regeneration. *J Neurosci Res* 80:37–46.
- Pareek S, Notterpek L, Snipes GJ, Naef R, Sossin W, Laliberté J, Iacampo S, Suter U, Shooter EM, Murphy RA (1997) Neurons promote the translocation of peripheral myelin protein 22 into myelin. *J Neurosci* 17:7754–7762.
- Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontés M (2004) Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. *Nat Med* 10:396–401.
- Peirano RI, Wegner M (2000) The glial transcription factor Sox10 binds to DNA both as monomer and dimer with different functional consequences. *Nucleic Acids Res* 28:3047–3055.
- Perea J, Robertson A, Tolmacheva T, Muddle J, King RH, Ponsford S, Thomas PK, Huxley C (2001) Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. *Hum Mol Genet* 10:1007–1018.
- Reiprich S, Kriesch J, Schreiner S, Wegner M (2010) Activation of Krox20 gene expression by Sox10 in myelinating Schwann cells. *J Neurochem* 112:744–754.
- Robertson AM, Perea J, McGuigan A, King RH, Muddle J, Gabreëls-Festen AA, Thomas PK, Huxley C (2002) Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. *J Anat* 200:377–390.
- Rossant J, Zirngibl R, Cado D, Shago M, Giguère V (1991) Expression of a retinoic acid response element-hsplacZ transgene defines specific domains of transcriptional activity during mouse embryogenesis. *Genes Dev* 5:1333–1344.
- Sabéran-Djoneidi D, Sanguedolce V, Assouline Z, Lévy N, Passage E, Fontés M (2000) Molecular dissection of the Schwann cell specific promoter of the PMP22 gene. *Gene* 248:223–231.
- Schreiner S, Cossais F, Fischer K, Scholz S, Bösl MR, Holtmann B, Sendtner M, Wegner M (2007) Hypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences in glial lineages. *Development* 134:3271–3281.
- Sereda M, Griffiths I, Pühlhofer A, Stewart H, Rossner MJ, Zimmerman F, Magyar JP, Schneider A, Hund E, Meinck HM, Suter U, Nave KA (1996) A transgenic rat model of Charcot-Marie-Tooth disease. *Neuron* 16:1049–1060.
- Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA (2003) Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). *Nat Med* 9:1533–1537.
- Slutsky SG, Kamaraju AK, Levy AM, Chebath J, Revel M (2003) Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype. *J Biol Chem* 278:8960–8968.
- Snipes GJ, Suter U, Welcher AA, Shooter EM (1992) Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13). *J Cell Biol* 117:225–238.
- Suter U, Scherer SS (2003) Disease mechanisms in inherited neuropathies. *Nat Rev Neurosci* 4:714–726.
- Suter U, Snipes GJ, Schoener-Scott R, Welcher AA, Pareek S, Lupski JR, Murphy RA, Shooter EM, Patel PI (1994) Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. *J Biol Chem* 269:25795–25808.
- Svaren J, Meijer D (2008) The molecular machinery of myelin gene transcription in Schwann cells. *Glia* 56:1541–1551.
- Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chenoufi AB, Seitanidou T, Babinet C, Charnay P (1994) Krox-20 controls myelination in the peripheral nervous system. *Nature* 371:796–799.
- Verrier JD, Lau P, Hudson L, Murashov AK, Renne R, Notterpek L (2009) Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a. *Glia* 57:1265–1279.
- Visel A, Blow MJ, Li Z, Zhang T, Akiyama JA, Holt A, Plajzer-Frick I, Shoukry M, Wright C, Chen F, Afzal V, Ren B, Rubin EM, Pennacchio LA (2009) ChIP-seq accurately predicts tissue-specific activity of enhancers. *Nature* 457:854–858.
- Werner MH, Huth JR, Gronenborn AM, Clore GM (1995) Molecular basis of human 46X,Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex. *Cell* 81:705–714.
- Zorick TS, Syroid DE, Arroyo E, Scherer SS, Lemke G (1996) The transcription factors SCIP and Krox-20 mark distinct stages and cell fates in Schwann cell differentiation. *Mol Cell Neurosci* 8:129–145.